We're headed to the ASCPT 2025 Annual Meeting! Schedule a time to chat with us at the event.

Non-liquid matrices are the future of bioanalysis, and Veloxity Labs is leading the charge. Read the report.

The 2025 FDA Biomarker Guidance is finally here, but it’s not without its gaps. Read our report for a breakdown of what’s new, what’s missing, and what it means for your biomarker strategy.

We’re headed to NorCal SOT Spring Symposium! Veloxity Labs is a proud sponsor—come see how we’re moving at the speed of bioanalysis.

Veloxity Labs announced exceptional year-over-year growth for Q1 2025, reflecting the company’s unique founder-funded, founder-operated model, culture of shared success and an unwavering commitment to operational excellence.

Check out this QAU audits report to learn more about how our systems and processes allow us to proactively address any challenges, collaborate with principal investigators (PIs) and continuously refine our workflow to drive better outcomes for you!

Read this report for a detailed comparison between conventional pharmacokinetic/toxicokinetic (PK/TK) workflows and a modern, fully integrated approach.

Veloxity Labs is seeking a Sample Coordinator to join their team. See if you're a fit!

Veloxity Labs is seeking an Associate Scientist I or II to join their team. See if you're a fit!

Download this report to learn how we leverage velocity to achieve optimal outcomes, maintain the highest standards and more.

Stop by Booth #54 at WRIB 2025 to discover how we can support your preclinical & clinical studies with speed, precision and compliance.

Download this report to gain valuable insights into the complexities of bioanalysis in medical device studies and more.

Veloxity Labs is proud to sponsor the upcoming PBSS Biotech Seminar Luncheon on April 1 at the Seattle Asian Art Museum.

In this video, Chris Tudan, PhD, breaks down the recent breakthroughs in adopting the ICH M10 guidance for animal health bioanalysis.

Download our report to explore the importance of bioanalytical turnaround times, why they matter to your project timelines and more.

Read our brochure to find out why clients turn to our bioanalytical CRO for fast start-up times, a foundation of quality, and more.

The partnership with Aplos promises groundbreaking enhancements to pharmacokinetic (PK) and toxicokinetic (TK) analysis for lightning-fast,

Link your bioanalysis with noncompartmental analysis (NCA) for comprehensive insights – all at once, without the wait!

Learn how backlog can signal growth—or reveal risks like delays & client dissatisfaction.

Our client-driven backlog approach ensures faster project start times and streamlined operations. Discover why it’s a game-changer.